Latar Belakang. Sebagian besar pasien kanker akan mengalami neuropati. Gejalaneuropatik yang muncul akibat kemoterapi dapat menghambat proses terapi.Cisplatin merupakan kemoterapi yang paling banyak digunakan dalam terapikanker nasofaring (KNF) dan banyak menyebabkan neuropati perifer. Penelitianini bertujuan untuk mengetahui gambaran neuropati pada pasien KNF yangmendapat kemoterapi di RSUPN Cipto Mangunkusumo serta faktor-faktor yangmempengaruhinya.Metode. Subyek penelitian ini adalah pasien KNF yang dikemoterapi dengancisplatin kurang dari 6 bulan sebelum pemeriksaan, baik tunggal, sebagaikemoadjuvant maupun kombinasi dengan kemoterapi lain yang tidakmenyebabkan neuropati perifer. Pasien Diabetes Mellitus serta gangguanneurologis sebelumnya disingkirkan dari penelitian. Dilakukan anamnesis,pemeriksaan fisik neurologis, dan elektroneurografi (ENG). Penelitian dilakukandengan menggunakan desain potong lintang. Pengumpulan data dilakukan padabulan Februari hingga Mei 2013.Hasil. Sebanyak 100 subyek penelitian yang terdiri dari 81 subjek laki-laki dan 19subyek perempuan diikutsertakan dalam penelitian ini. Usia dari subjek penelitianberkisar antara 30-60 tahun. Didapatkan 76% subjek mengalami neuropati, 51subjek diantaranya mengalami neuropati ENG, 25 subjek mengalami neuropatisecara klinis dan ENG. Didapatkan neuropati sensorik 82.89%, neuropati motorik80,26%, dan 51,32% mengalami neuropati otonom. Berdsarkan tipenya 89,47%mengalami degenerasi aksonal dan tidak satupun mengalami yang mengalamidemielinisasi murni. Secara statistik terdapat hubungan yang bermakna antara usiadan dosis dengan kejadia neuropati secara klinis (masing-masing p < 0,05).Kesimpulan. Telah didapatkan yang mendapat kemoterapi cisplatin di RSUPNCipto Mangunkusumo termasuk tinggi yaitu sebesar 76%, dan hanya 25% yangmengalami gejala neuropati secara klinis. Lebih dari setengah (51%) pasienmengalami neuropati subklinis prevalensi neuropati perifer. Neuropati sensorikmerupakan neropati paling banyak terjadi. Hampir semua pasien yang mendapatkemoterapi cisplatin mengalami neuropati aksonal. Usia lebih tua dan dosis totalyang lebih besar merupakan faktor-faktor yang mempengaruhi neuropati padapasien KNF yang mendapat kemoterapi cisplatin

---

Background. The majority of cancer patients will experience neuropathy.

Neuropathic symptoms arising from chemotherapy can inhibit the therapeutic

process. Cisplatin is the most widely used chemotherapy in the treatment of

nasopharyngeal cancer (NPC) and the many causes of peripheral neuropathy. This

study aims to describe the neuropathy in NPC patients who received

chemotherapy in Cipto Mangunkusumo and the factors that influence it.

Method. The study subjects were NPC patients whose chemotherapy with

cisplatin less than 6 months before the examination, whether single, as

kemoadjuvant or in combination with other chemotherapy that does not cause

peripheral neuropathy. Diabetes Mellitus and patients with neurological disorders

previously excluded from the study. Anamnesis, neurological physical

examination, and elektroneurografi (ENG) were done. The study was conducted

using a cross-sectional design. The data was collected between February and May

2013.

Results. A total of 100 study subjects consisted of 81 male subjects and 19 female

subjects were included in this study. Age of study subjects ranged from 30-60

years. There were 76% of the subjects had neuropathy, 51 subjects had

neuropathy based on ENG only, 25 subjects based on clinical and ENG. There

were 82.89% had sensory neuropathy, 80.26% had motor neuropathy, and 51.32%

had autonomic neuropathy. Most (89.47%) had axonal degeneration and none had

the experience of pure demyelination. There is a statistically significant

relationship between age and dose with the incidence of clinical neuropathy (each

p <0,05).

Conclusion. The prevalence of neuropathy in cisplatin chemotherapy in NPC

patients in Cipto Mangunkusumo was as high as 76%, and only 25% who

experienced clinical symptoms. More than half (51%) patients had subclinical

neuropathy of peripheral neuropathy. Older age and greater total doses are all

factors that influence the KNF neuropathy in patients receiving cisplatin

chemotherapy.